Journal of Chemistry
Volume 2018 (2018), Article ID 1523154, 7 pages
https://doi.org/10.1155/2018/1523154

Research Article

Fabrication of a Porous Metal-Organic Framework with Polar Channels for 5-Fu Delivery and Inhibiting Human Osteosarcoma Cells

Li-Chun Zhao, Mei Tang, Qian-Hua Zhang, Zhi-Yi Hu, Hong-Wei Gao, Xia-Yun Liao, Gang Wang, and Jing Leng

College of Pharmacy, Guangxi University of Chinese Medicine, Nanning 530200, China

Correspondence should be addressed to Jing Leng; jing_leng666@126.com

Received 24 May 2018; Accepted 2 July 2018; Published 25 July 2018

Academic Editor: Maria F. Carvalho

Copyright © 2018 Li-Chun Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

As an emerging kind of crystalline material, the metal-organic framework (MOF) has shown great promise in the biomedical domains such as drug storage and delivery. In this study, a new porous MOF, [[Dy₂(H₂O)₃(SDBA)₃](DMA)₆] (1, H₂SDBA = 4,4′-sulfonyldibenzoic acid, DMA = N,N-dimethylacetamide (C₄H₉NO)), with uncoordinated O donor sites has been fabricated using a bent polycarboxylic acid organic linker under the solvothermal condition. The structure of the obtained crystalline product has been fully determined by the X-ray single-crystal diffraction, TGA, elemental analysis, XRD, and the gas sorption measurement. Due to the suitable window size and polar atom functionalized 1D channels, the activated 1 (1a) compound was used for the anticancer drug 5-fluorouracil (5-Fu, C₄H₃FN₂O₂) loading by a simple impregnation method. A moderate drug loading and pH-dependent drug-release behavior could be observed for 1a. Furthermore, as indicated by the MTT assay, this drug/MOF composite shows low toxicity toward the human normal cells and demonstrates obvious anticancer activity against the human osteosarcoma cell line MG63.

1. Introduction

Being one of the most life-threatening diseases, cancer has caught the nerves of people all over the world because more and more people are suffering from cancer and die from it [1]. Currently, the most effective treatment method is still chemotherapy which relies on the anticancer drugs [2]. However, chemotherapy has always suffered some unbearable drawbacks such as nonspecific toxicity toward normal cells, poor solubility of the chemotherapy drug, and undesirable side effects [3]. In this case, great notice has been devoted to nanocarriers for anticancer drug delivery for cancer therapy, aiming at a targeted release of anticancer drugs while retarding the drug leaking into the healthy physiological environment [4]. The uncommon microenvironments at tumor sites such as low pH value, high glutathione (GSH) concentration, and different oxygen concentrations can be utilized to trigger drug release from the carriers.

As an emerging kind of crystalline material, the metal-organic framework (MOF) built via the assembly of organic ligands as bridges and metal ions as nodes has underwent a rapid development in the last two decades [5–7]. Recently, porous metal-organic frameworks have been proved to be very successful for drug delivery, possessing advantages such as high drug-loading capacity, suitable pore size, and strong drug-framework interaction [8, 9]. Furthermore, the toxicity of the MOFs toward the human normal cells can be tactfully averted by selecting biocompatible metals and organic ligands. In addition, the pore walls of MOFs could be conveniently gifted polar donor sites via selecting organic ligands with polar donor sites, which could form strong framework-drug interaction to result in the sustainable drug-release behavior. For instance, the anticancer drug-loaded ZIF-8 nanocarriers showing pH-sensitivite drug release have been achieved by Zhao and coworkers [10]; Kotzabasaki et al. revealed that the hydroxyl groups in IRMOF-16 could lead to a much improved drug-loading capacity, which outperforms many other materials targeted for the gemcitabine loading [11]. With the aim in mind of developing novel drug carriers, in this study, a new porous MOF, [[Dy₂(H₂O)₃(SDBA)₃](DMA)₆] (1, H₂SDBA = 4,4′-sulfonyldibenzoic acid; Figure 1), with uncoordinated O donor sites has been fabricated using a bent polycarboxylic acid organic linker under the solvothermal condition. Although the H₂SDBA ligand has been used in building the Dy-based coordination compounds in the previous literature, none of them are porous structures [12]. The structure of the obtained crystalline product has been fully characterized by the X-ray single-crystal diffraction, elemental analysis, TGA, XRD, and the gas sorption measurement. Due to the suitable window size and polar atom functionalized 1D channels, the activated 1 (1a) was used for the anticancer drug 5-Fu loading by a simple impregnation method. A moderate drug-loading and sustainable drug-release behavior could be observed for 1a. Furthermore, as indicated by the MTT assay, this drug/MOF composite shows low toxicity toward the human normal cells and demonstrates obvious anticancer activity against the human osteosarcoma cell line MG63.

Figure 1: The chemical drawing of 4,4′-sulfonyldibenzoic acid (H₂SDBA) ligand used in the construction of 1.

2. Experimental

2.1. Chemicals and Instruments

All the chemicals are obtained from the regent companies and used as received. Elemental analyses (C, H, and N) were carried out with a Vario EL III Elemental analyzer. Powder X-ray diffraction (PXRD) curves were collected on a Difrac Plus XRD Commander diffractometer at room temperature. Measurements of the UV-Vis absorption spectra were carried out in a quartz cell using a Camspec M330 UV-Vis spectrometer. Thermal gravity analysis (TGA) curves were collected using a NETZSCH STA449F3 thermal analyzer. The N₂ sorption data at 77 K were collected on the Autosorb 1 by Quantachrome. The HPLC analysis was conducted using the 1260 Agilent chromatographic system.

2.2. Preparation of [[Dy₂(H₂O)₃(SDBA)₃](DMA)₆]

In a 50 mL beaker, Dy(NO₃)·6H₂O (46 mg, 0.1 mmol), H₂SDBA (31 mg, 0.1 mmol), DMA (6 mL), and H₂O (1.5 mL) were added. After the addition of 0.2 mL HCl (2 M aq.), the mixture was stirred for 30 min in the air to make a clear solution, and then, the mixture was placed in a 20 mL vial and kept at 90°C for two days. Yellow sheet crystals of 1 were obtained by filtration, washed with water, and left in the air for one day to make them dry. The yield was 46% based on the H₂SDBA ligand. Elemental analysis (%): calcd. for 1 (C₆₆H₈₄Dy₂N₆O₂₇S₃): C, 43.69; H, 4.67; and N, 4.63; found: C, 43.19; H, 4.28; and N, 4.66.

2.3. Crystal Structure Determination

The X-ray single-crystal diffraction data of 1 were collected on the Oxford diffraction Xcalibur CCD diffractometer with Mo Kα radiation. The structural model of 1 was solved by direct methods using the SHELXT program, and the obtained model was amended using the SHELXL program. All hydrogen atoms attached to oxygen and carbon were generated geometrically and all non-hydrogen atoms were refined anisotropically. For the disordered nature of the DMA molecules, they could not be figured out from the structural model, so their electrons were removed from the HKL file using the SQUEEZE manipulation in the software PLATON (the total unit cell includes six DMA molecules (48e ∗ 6 = 288e), and the SQUEEZE result reveals that 596 electrons were removed from the unit cell). This discrepancy might be owing to the different measurement conditions for the single-crystal X-ray analysis (tested after being sealed in a capillary filled with DMA) and TGA (tested after being dried in the air)). The solvents in the chemical formula of 1 were determined from the TGA curve and elemental analysis results. Relevant data concerning the crystal data and refinement parameters have been provided in Table 1.

Table 1: Crystal data and structure refinements for compound 1.

Formula
C₄₂H₃₀Dy₂O₂₁S₃

Mr
1291.84

T (K)
293 (2)

Crystal system
Monoclinic

Space group
P2₁/c

α (°)
90

β (°)
110.892 (3)

γ (°)
90

a (Å)
18.2117 (4)

b (Å)
21.2418 (5)

c (Å)
16.1128 (4)

Volume (Å³)
5823.4 (3)

Z
2

Dcalc (g·cm⁻³)
1.473

μ (Mo Kα) (mm⁻¹)
2.719

θ range (°)
2.347 to 24.990

Reflections collected
20165

Rint
0.0264

Data number with I ≥ 2σ(I)
7483

R₁
0.0251

ωR₂ (all data)
0.0558

CCDC
1844814

2.4. 5-Fu Loading and Release

Twenty milligrams of activated 1 (1a) were suspended in 8 ml of 5-Fu solutions, and then, the mixture suspensions were stirred for 72 h at 37°C. Finally, 5-Fu-loaded 1a was obtained through centrifugation for 5 min, washed with MeOH, and dried at room temperature. 1a before and after the 5-Fu entrapping were characterized by PXRD. The concentration of 5-Fu in the supernatant was determined by the absorbance of 5-Fu at 265 nm with the help of a calibration curve. Then, the drug-loading efficiency was calculated. Drug encapsulation efficiency = (total amount − without loading amount)/total amount × 100%. The 5-Fu release experiment was compacted in the dialysis bag. The 5-Fu-loaded crystals of 1 were soaked in the PBS solution at different pH values (7.4 and 5.6) at 37°C. In each interval, 0.2 mL of the solution was taken out and fresh PBS with equal amount was added. Then, the 5-Fu content was probed using the HPLC analysis.

2.5. GCMC Simulation

The adsorption process of the 5-fluorouracil (5-Fu) molecule to 1a was investigated using grand canonical Monte Carlo (GCMC) simulations at 300 K. Interactions of 5-Fu with the frameworks were described by a potential composed of van der Waals and Coulomb components. Van der Waals interactions were treated using the Lennard–Jones (LJ) potential and atomic parameters taken from the UFF force field. Coulomb interactions were calculated using atomic partial charges obtained via the charge equilibration (Qeq) method proposed by Snurr and coworkers. Partial charges for 5-Fu molecules were calculated at the B3LYP level using the DMOL3 module. GCMC simulations were carried out with 1 × 10⁷ equilibration steps and 2 × 10⁷ production steps. The configuration-bias Monte Carlo method was used for trial MC moves involving insertion and deletion of 5-Fu molecules. All GCMC simulations were performed using the sorption module embedded in Material Studio 6.1.

2.6. In Vitro Toxicity Tests

The cytotoxicity toward HASM (human aortic smooth muscle) cells and MG63 cells was determined using MTT assays. The cells were seeded in a 96-well microplate. After 24 h of cell attachment, the cells were treated and incubated with different concentrations of each complex for 48 h. Then, 25 μl of MTT solution was added into each well. After the cells were incubated for another 4 hours, 150 μl of DMSO was added to each well to dissolve the MTT formazan crystals. At last, the absorbance of each well was monitored through a microplate reader.

3. Results and Discussion

3.1. Molecular Structure and Physical Characterization of 1

Crystallographic analysis via the X-ray single-crystal diffraction reveals that compound 1 locates in the monoclinic crystal system and P2₁/c space group and shows a three-dimensional channel-type framework. The molecular unit is composed of two independent Dy(III) ions, three SDBA²⁻ ligands, and three coordinated water molecules. As plotted in Figure 2(a), eight O atoms from six different SDBA²⁻ ligands (O1, O5, O6, O7, O7A, O8, and O12) and one coordinated water molecule (O2W) form the DyO8 coordination surrounding, with the Dy1-O bond distances ranging from 2.215 (3) to 2.619 (3) Å; Dy2 is also an eight-atom connected compound with six O atoms from five independent SDBA²⁻ ligands (O2, O11, O13, O14, O17, and O18) and two O atoms of the coordinated water molecules (O1W and O3W), with the Dy2-O bond lengths ranging from 2.249 (2) to 2.531 (3) Å. All the Dy-O bond distances are comparable to those observed in the Dy-based metal-organic frameworks. The Dy1, Dy2, and their symmetry-related atoms are held together via the syn-bridging carboxylic groups along the a-axis to afford the 1D secondary building unit chains with the Dy1-Dy2 separation of 5.04 Å. As for the SDBA²⁻ ligands, they exhibit three different coordination modes with the two carboxylic groups binding with one or two Dy³⁺ ions forming paddle-wheel units (Figure 2(b)). The SDB ligands are bent with the C-S-C bond angles ranging from 101.7 (2) to 103.6 (2)°, which connect with the 1D SUB channels to afford the three-dimensional framework with rhombus channels (Figure 2(c)). The channels are filled with uncoordinated O donors site and water-occupied Dy(III) sites, which are potentially favorable for guests binding. The total effective solvent accessible volume is 2172 Å³, corresponding to 37.3% of the cell volume. In the framework of 1, the three SDBA²⁻ ligands in the molecular unit could be judged as 3-,4-, and 5-connected nodes, and the two Dy(III) ions could be viewed as 5- and 6-connected nodes; so the whole framework of 1 can be abstracted as a 3-, 4-, 4-, 5-, and 6-connected topological network with the Schläfli symbol of {4.6.8}{4 ^ 2.6 ^ 3.8 ^ 5}{4 ^ 3.6 ^ 2.8}{4 ^ 3.6 ^ 3}{4 ^ 9.6 ^ 6}, which has not been included in the TOPOS database (Figure 2(d)).

(a)

(b)

(c)

(d)

Figure 2: (a) The coordination surroundings for the Dy(III) ions in 1; (b) view of the binding pattern for the SDBA ligands; (c) view of the 3D network of 1; (d) 3-, 4-, 4-, 5-, and 6-connected net of 1.

In order to determine the obtained 1 more fully in terms of phase purity and thermal stability, we carried out the PXRD measurements and TGA experiments. As shown in Figure 3(a), the good match between the simulated and experimental PXRD patterns indicates the high phase purity of the as-synthesized 1. Considering the following drug delivery experiments, the stability of 1 in water has been checked by soaking the crystalline samples of 1 in water for one day, and then, the corresponding PXRD patterns were collected, which reveal that the water surroundings could not lead to the transformation of the framework of 1, confirming its good water stability. To probe the lattice solvents in the framework of 1, the TGA experiments were carried out (Figure 3(b)). A weight loss of 32.3% was observed in the temperature range of 25 to 429°C, which can be attributed to the release of three coordinated water and six lattice DMA molecules. After reaching 429°C, a sharp weight loss could be observed for 1, which indicates the collapse of the framework. To establish the permanent porosity of the solvent-free samples of 1 (1a), the as-prepared crystalline samples of 1 were soaked in the anhydrous MeOH for three days to exchange with the lattice DMA molecules, and then activated at 60°C for 12 hours. The full activation of 1a has been confirmed via the TGA experiments, which reveals that no obvious weight loss could be found in the temperature range of 25 to 429°C. To determine the surface area of 1a, N₂ sorption isotherm was collected at 77 K. 1a shows a type-I sorption behavior with the maximum N₂ uptake capacity of 294 cm³/g, which indicates complex 1a is a microporous material (Figure 3(c)). The Brunauer–Emmett–Teller (BET) surface area was calculated to be 1222 m²/g, indicating the space of 1a could house considerable amount of guest molecules. Furthermore, the hole diameter and distribution calculated from the 77 K N₂ sorption method reveals a hole size distribution around 0.95 nm, illuminating the potential of accepting guests in the pores (Figure 3(d)).

(a)

(b)

(c)

(d)

Figure 3: (a) The PXRD patterns of 1 and its different forms; (b) TGA curves of 1 and 1a; (c) N₂ sorption isotherms of 1 and 1a; (d) hole size location of 1a derived from the N₂ sorption data at 77 K.

3.2. Drug Delivery Experiment

In light of its large BET surface area and suitable pore size, complex 1a has the potential for loading small guest molecules. In this work, 5-fluorouracil (5-Fu) with the molecular size of 5.3 × 5.0 Å² was chosen as the guest molecules because it is a widely used drug molecule for the cancer treatment. The drug-loading experiments were carried out by impregnating of 1a (10 mg) in 5 mL MeOH solution containing 20 mg of 5-Fu with consciously stirring for two hours, and then, the 5-Fu concentration in the MeOH solution was detected via the UV-Vis spectroscopy. As shown in Figure 4(a), there is an obvious decrease in the intensity of the UV-Vis spectrum at 254 nm, indicating that the 5-Fu molecules are absorbed into the pores of 1a (Figure 4(a)). The 5-Fu storage capacity is 20.6 wt.% (this means every 100 g of 5-Fu/1a composite contains 20.6 g of 5-Fu) based on the UV-Vis spectrum result. Furthermore, the N₂ sorption experiment of the 5-Fu-loaded 1a indicates that it could hardly adsorb any N₂ under the given conditions, revealing that the pore spaces of 1a are effectively occupied by the drug molecules.

(a)

(b)

(c)

(d)

Figure 4: (a) UV-Vis spectra of the MeOH solution containing 5-Fu before and after loading the drug; (b) drug releasing curves under different pH values; (c) simulated binding site of 5-Fu in the framework of 1 at zero loading; (d) locations of the 5-Fu molecules in the framework of 1 at 37°C and 100 kPa.

The drug sustained-release experiment was studied under different conditions (pH 7.4 at 37°C and pH 5.6 at 37°C), and the 5-Fu released concentration was determined by HPLC. As shown in Figure 4(b), the amount of 5-Fu released from 5-Fu-loaded 1a is 50% in the first 40 h, and further increasing the time could not lead to more 5-Fu released from the carrier. The present result also indicates that the 5-Fu drug could not be completely released from the carrier under the present conditions. When the pH value of the PBS solution was adjusted to 5.6, it could be observed that the release rate is much faster with nearly 70% of 5-Fu molecules being released into the solution, indicating that the 5-Fu release is pH independent (Figure 4(b)). The slightly large release rate might be due to the partly decomposition of the framework. To understand the interaction between the 5-Fu molecules and the framework, the GCMC simulation was carried out. As shown in Figure 4(c), the simulated favorable binding site of 5-Fu at zero loading indicates that the one 5-Fu molecule prefers to locate in the channel center with short H-bond and Dy-O interactions could be observed (2.991 Å and 2.915 Å). Furthermore, besides the H-bond interactions, there also exists π-π interaction between the 5-Fu molecule and the benzene ring of the ligand with a distance of 3.370 Å. All these interactions contribute to the strong binding energy of 5-Fu with the framework, resulting in the long-lasting drug release. Figure 4(d) shows the distribution of 5-Fu molecules in the framework of 1a at 37°C and 100 kPa, which reveals that each unit cell of 1 could house 11 5-Fu molecules, corresponding to 22.4 wt.%, which is near to the value calculated from the UV-Vis spectrum.

3.3. Anticancer Activity

As a drug delivery system, its cytotoxicity toward the human normal cells should be considered. With this in consideration, the cytotoxicity of the 5-Fu-loaded 1a and the 5-Fu were studied against the HASM (human aortic smooth muscle) cells via the standard MTT method. The HASM cells were incubated with 5-Fu-loaded 1a and 5-Fu with various concentrations, and the corresponding cell viabilities were recorded. As shown in Figure 5(a), the cell viabilities are all above 92% under various concentrations of 5-Fu-loaded 1a, indicating that this drug-MOF composite has little toxicity toward the human normal cells. Furthermore, compared with the drug 5-Fu, the drug-MOF composite shows more cell viability, illuminating that the drug-MOF might possess less side effect compared with the pure drug. To probe the anticancer activity of the 5-Fu-loaded 1a, the in vitro antitumor activity was studied against the human osteosarcoma cell line MG63 under different concentrations for 24 h and 48 h, respectively. As shown in Figure 5(b), the 5-Fu-loaded 1a exhibits potent cytotoxicities against the MG63 cells, with about 60% cancer cells killed at 24 h. Interestingly, further prolonging the experimental time could lead to more cell death, indicating the long-lasting drug release.

(a)

(b)

Figure 5: (a) HASM cell viability after exposure to 5-Fu-loaded 1a and 5-Fu at different concentrations after 24 h; (b) viability of MG63 cells after incubation with various concentrations of drug-loaded MOF at 24 h and 48 h.

4. Conclusion

In summary, we have successfully prepared a novel porous MOF using a V-shaped polycarboxylic acid organic linker under the solvothermal condition. The as-prepared MOF is composed of 1D chain-like SBUs that were linked via the ligands to afford the 3D framework with 1D microporous channels running along the a-axis. Due to its suitable pore size and high density of O donor sites, it could behave as an effective carrier for the 5-Fu capture and release, and a moderate 5-Fu-loading capacity and pH-dependent drug release behavior could be observed. Furthermore, the MTT assay reveals the low cytotoxicity of the 5-Fu-loaded 1a and notable anticancer activity against the human osteosarcoma cell line MG63.

Data Availability

The data used to support the findings of this study are included within this article.

Conflicts of Interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

References

J. Öhlén, J. Cohen, and C. Håkanson, “Determinants in the place of death for people with different cancer types: a national population-based study,” Acta Oncologica, vol. 56, no. 3, pp. 455–461, 2017.

J. Bogach, O. Levine, S. Parpia, M. Valencia, L. Ruo, and P. Serrano, “Does the addition of biologic agents to chemotherapy in patients with unresectable colorectal cancer metastases result in a higher proportion of patients undergoing resection? A systematic review and meta-analysis,” Journal of Gastrointestinal Surgery, vol. 22, no. 3, pp. 523–528, 2018.

J. Zhou, G. Yu, and F. Huang, “Supramolecular chemotherapy based on host–guest molecular recognition: a novel strategy in the battle against cancer with a bright future,” Chemical Society Reviews, vol. 46, no. 22, pp. 7021–7053, 2017.

L. Wang, M. Zheng, and Z. Xie, “Nanoscale metal–organic frameworks for drug delivery: a conventional platform with new promise,” Journal of Materials Chemistry B, vol. 6, no. 5, pp. 707–717, 2018.

D. Rambabu, P. Negi, A. Dhir, A. Gupta, and Pooja, “Fe(III) and Cu(I) based metal organic gels for in situ drug loading and drug delivery of 5-fluorouracil,” Inorganic Chemistry Communication, vol. 93, pp. 6–9, 2018.

Y. Georgiou, J. A. Perman, A. B. Bourlinos, and Y. Deligiannakis, “Highly efficient arsenite [As(III)] adsorption by an [MIL-100(Fe)] metal–organic framework: structural and mechanistic insights,” Journal of Physical Chemistry C, vol. 122, no. 9, pp. 4859–4869, 2018.

A. C. Forse, M. I. Gonzalez, R. L. Siegelman et al., “Unexpected diffusion anisotropy of carbon dioxide in the metal–organic framework Zn2 (Dobpdc),” Journal of American Chemical Society, vol. 140, no. 5, pp. 1663–1673, 2018.

J. Liu, T. Y. Bao, X. Y. Yang et al., “Controllable porosity conversion of metal-organic frameworks composed of natural ingredients for drug delivery,” Chemical Communications, vol. 53, no. 55, pp. 7804–7807, 2017.

X. Du, R. Fan, L. Qiang et al., “Controlled Zn²⁺-triggered drug release by preferred coordination of open active sites within functionalization indium metal organic frameworks,” ACS Applied Materials and Interfaces, vol. 9, no. 34, pp. 28939–28948, 2017.

Y. Duan, F. Ye, Y. Huang, Y. Qin, C. He, and S. Zhao, “One-pot synthesis of a metal–organic framework-based drug carrier for intelligent glucose-responsive insulin delivery,” Chemical Communications, vol. 54, no. 42, pp. 5377–5380, 2018.

M. Kotzabasaki, E. Tylianakis, E. Klontzas, and G. E. Froudakis, “OH-functionalization strategy in metal-organic frameworks for drug delivery,” Chemical Physics Letters, vol. 685, pp. 114–118, 2017.

R. Łyszczek, A. Ostasz, A. Bartyzel, and A. Lipke, “Thermal, Spectroscopic and Luminescence Investigations of lanthanide(III) coordination polymers based on v-shaped 4,4′-sulfonyldibenzoic acid,” Journal of Analytical Applied Pyrolysis, vol. 115, pp. 370–378, 2015.